Celltrion: Celltrion to unveil next-generation antibody drug technologies at AACR 2025
Celltrion and Celltrion Pharm said that they will jointly participate in the 2025 American Association for Cancer Research (AACR) Annual Meeting, set to take place from April 25 to 30 in Chicago.Celltrion is scheduled to present preclinical results of its multispecific antibody candidate, CT-P72, fo
Read full article »
CEO
Kee Woo-sung
Celltrion is a South Korea-based pharmaceutical firm that develops and commercializes medicinal drugs for the treatment of diseases such as cancer and autoimmune.
Read more